Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET

An new low in eighteen years! Tonghua Dongbao Pharmaceutical expects last year's net income to decline by more than 90% year-on-year, and Q4 performance may not meet expectations | Interpretations

① Affected by the decline in sales revenue due to product price reductions, as well as the termination of research and development projects, Tonghua Dongbao Pharmaceutical expects that its net income attributable to the parent for 2024 will decrease by more than 90% year-on-year. ② Compared to Q4, net income saw a decline quarter-on-quarter, and may not have met the company's previous expectations.

cls.cnJan 20 08:40 ET

Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.

① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.

cls.cnJan 16 08:15 ET

Main business income declined, Staidson is expected to report a loss of up to 0.15 billion in 2024 | Interpretations

① Staidson expects revenue in 2024 to decrease by 19.78%-1.95% year-on-year, with a net loss attributable to shareholders of 0.148 billion yuan-0.121 billion yuan, which is a narrowing compared to 2023. ② To integrate resources and reduce costs and increase efficiency, Staidson will deregister three loss-making subsidiaries in 2024.

cls.cnJan 15 10:22 ET

The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.

① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.

cls.cnJan 15 09:53 ET

WUXI XDC's net income for 2024 is expected to increase by 260%. WUXI APPTEC recently cashed out 2.4 billion Hong Kong dollars at a high point | Quick read of the announcement.

In 2024, WUXI XDC expects total revenues, Net income, and adjusted Net income to grow by over 85%, 260%, and 170% year-on-year, respectively; According to the latest data from Frost & Sullivan, it is projected that by 2030, the Global market size for ADC and XDC will reach 66.2 billion US dollars.

cls.cnJan 15 00:06 ET